More and more studies show that men face risks of cancer from BRCA1 and BRCA2 genetic mutations that are most often associated with breast and ovarian cancers in women. "Not enough men are getting ...
The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...
Deescalated nab-paclitaxel plus carboplatin showed higher efficacy than nab-paclitaxel plus gemcitabine in early-stage TNBC patients. BRCA1/2 mutation carriers exhibited a more pronounced pathologic ...
Among young women carrying germline BRCA1/2 pathogenic or likely pathogenic variants diagnosed with early-onset breast cancer, bilateral mastectomy rates increased substantially over two decades, ...
Researchers have discovered factors that may make breast and ovarian cancers associated with BRCA1/2 gene mutations more likely to recur. Researchers at the University of Pennsylvania's Basser Center ...
GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico ...
A Phase 1 trial found that combining the ATR inhibitor ceralasertib with the PARP inhibitor olaparib was generally well ...
Researchers have uncovered how tumor cells interact with the immune system in ovarian cancer. Utilizing highly multiplex immunofluorescence and image analysis, they investigated how the genetic ...
Metastatic breast cancer has a poor prognosis, but emerging targeted therapies are providing some progress in the treatment of the disease, explained Filipa Lynce, MD, medical oncologist at ...
Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer. One year after standard-of-care treatment including surgery, chemotherapy, hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results